System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Michael E Wechsler is an expert in Immunology at National Jewish Health (United States). As of October 2026, ScienceLeadR ranks Michael E Wechsler in the top 1% of experts worldwide for Asthma, Hypersensitivity and Eosinophilia. Michael E Wechsler has authored 446 publications, the most recent in 2026, and is an investigator in 45 clinical trials, 2 of them ongoing. SLR score: 2,756 (community average: 125). How the SLR is computed.

LeadR Profile

Michael E Wechsler National Jewish Health United States
2 756 ScienceLeadR Reputation 2756

Unlock

Register Login
Network Map

Immunology

Subspecialties: Pulmonology - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026
Source: PubMed

National Jewish Health

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 446

Citations

Citations: 24 082 1st author: 85 Last author: 83 Unique author: 15

Main journals

J Allergy Clin Immunol 75
J Allergy Clin Immunol Pract 38
Chest 34
Am J Respir Crit Care Med 32
N Engl J Med 21

Best Journals

N Engl J Med 21
Lancet Respir Med 10
JAMA 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pocket guide Biologics in upper and lower airway diseases 2026 by EUFOREA.
PMID 42878116 — pulmonary disease, chronic obstructive, therapeutics		Rhinology20260
Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.
PMID 42624803 — lung, blood, cohort studies, eosinophils, therapeutics, asthma, prospective studies		Lancet Respir Med Top journal20261
Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial.
PMID 42717393 — cells, hypersensitivity, eosinophils, biomarkers, therapeutics, asthma		Allergy20260
Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.
PMID 42638984 — therapeutics, asthma		J Asthma Allergy20260
Advances in the treatment of eosinophilic granulomatosis with polyangiitis.
PMID 42552373 — glucocorticoids, vasculitis, neutrophils, rheumatic diseases, signs and symptoms, antibodies, antineutrophil cytoplasmic, therapeutics, microscopic polyangiitis, granulomatosis with polyangiitis		Nat Rev Rheumatol Top journal20261

Clinical Studies 45

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 3 21
N/A 10
Phase 2 7
Phase 4 4
Phase 1/Phase 2 2
Phase 2/Phase 3 1

By status:

Completed 39
Active not recruiting 2
Terminated 2
Recruiting 1
Unknown 1

By type:

Interventional 40
Observational 5

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 2
multicentric5to9 4
multicentricup10 30

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
PULmonary Stimulation for Asthma Relief
NCT07709754 — safety, spinal cord, spinal cord stimulation, multiple chronic conditions, therapeutics, asthma, spine		N/ARecruiting2026
Study Assessing the Long term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287 — injections, lung, solutions, therapeutics, asthma, injections, subcutaneous		Phase 4Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS